- Home
- CCM vs SCYX Comparison
CCM vs SCYX Comparison
Compare CCM & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- SCYX
- Stock Information
- Founded
- CCM 1997
- SCYX 1999
- Country
- CCM China
- SCYX United States
- Employees
- CCM N/A
- SCYX N/A
- Industry
- CCM Medical/Nursing Services
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- SCYX Health Care
- Exchange
- CCM Nasdaq
- SCYX Nasdaq
- Market Cap
- CCM 33.3M
- SCYX 34.9M
- IPO Year
- CCM 2009
- SCYX 2014
- Fundamental
- Price
- CCM $5.64
- SCYX $1.04
- Analyst Decision
- CCM
- SCYX
- Analyst Count
- CCM 0
- SCYX 0
- Target Price
- CCM N/A
- SCYX N/A
- AVG Volume (30 Days)
- CCM 2.7K
- SCYX 136.2K
- Earning Date
- CCM 09-26-2025
- SCYX 11-05-2025
- Dividend Yield
- CCM N/A
- SCYX N/A
- EPS Growth
- CCM N/A
- SCYX N/A
- EPS
- CCM N/A
- SCYX N/A
- Revenue
- CCM $52,603,198.00
- SCYX $3,257,000.00
- Revenue This Year
- CCM N/A
- SCYX $422.61
- Revenue Next Year
- CCM N/A
- SCYX $240.56
- P/E Ratio
- CCM N/A
- SCYX N/A
- Revenue Growth
- CCM N/A
- SCYX N/A
- 52 Week Low
- CCM $3.80
- SCYX $0.66
- 52 Week High
- CCM $10.77
- SCYX $1.66
- Technical
- Relative Strength Index (RSI)
- CCM 55.42
- SCYX 77.62
- Support Level
- CCM $5.10
- SCYX $0.81
- Resistance Level
- CCM $5.99
- SCYX $0.88
- Average True Range (ATR)
- CCM 0.14
- SCYX 0.04
- MACD
- CCM 0.04
- SCYX 0.02
- Stochastic Oscillator
- CCM 60.67
- SCYX 92.31
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.